Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has signed another order worth more than 500 million Swiss francs – or $531...

Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.

Swiss peptide and oligonucleotide specialist Bachem has agreed to buy an undeveloped site in Sisslerfeld from DSM. It has completed the purchase of a first plot, with...

Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has announced the signing of two major contracts for supplying large volumes of...

Bachem, a Swiss specialist in the development manufacture and manufacture of peptides and oligonucleotides, has entered into a strategic collaboration with major...

The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this...

The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this...

Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding...